Veracyte (NASDAQ:VCYT) Stock Gets Price Target Trim from UBS Group

Veracyte (NASDAQ:VCYT) had its price objective decreased by UBS Group from $65.00 to $35.00 in a report released on Monday,Benzinga reports. UBS Group currently has a buy rating on the biotechnology company’s stock.

Other research analysts have also issued reports about the company. Piper Sandler decreased their target price on Veracyte from $66.00 to $54.00 and set an “overweight” rating on the stock in a report on Tuesday, August 4th. Weiss Ratings lowered shares of Veracyte from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, September 24th. Leerink Partners lowered shares of Veracyte from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $55.00 to $35.00 in a research report on Thursday, November 5th. Canaccord Genuity Group cut their target price on shares of Veracyte from $60.00 to $50.00 and set a “hold” rating for the company in a research note on Monday, August 3rd. Finally, Zacks Research downgraded shares of Veracyte from a “strong-buy” rating to a “hold” rating in a report on Friday, October 2nd. Six equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $44.50.

Veracyte Stock Performance

Shares of Veracyte stock opened at $25.11 on Monday. Veracyte has a 52-week low of $21.91 and a 52-week high of $60.91. The business’s 50 day simple moving average is $42.98 and its 200 day simple moving average is $42.59. The firm has a market cap of $2.03 billion, a PE ratio of 15.83 and a beta of 1.98.

Veracyte (NASDAQ:VCYT) last issued its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.10. The firm had revenue of $151.75 million for the quarter, compared to analyst estimates of $147.13 million. Veracyte had a net margin of 21.80% and a return on equity of 8.99%. The company’s revenue was up 15.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.51 EPS. As a group, equities research analysts predict that Veracyte will post 1.32 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Rebecca Chambers sold 3,652 shares of Veracyte stock in a transaction on Friday, September 4th. The stock was sold at an average price of $43.10, for a total value of $157,401.20. Following the transaction, the chief financial officer owned 166,025 shares in the company, valued at approximately $7,155,677.50. This trade represents a 2.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Leite sold 4,015 shares of Veracyte stock in a transaction on Monday, September 21st. The shares were sold at an average price of $40.00, for a total value of $160,600.00. Following the completion of the transaction, the insider owned 124,329 shares in the company, valued at approximately $4,973,160. The trade was a 3.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 62,609 shares of company stock valued at $2,858,904 over the last three months. 1.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Bank of America Corp DE raised its position in shares of Veracyte by 14.7% during the first quarter. Bank of America Corp DE now owns 1,448,897 shares of the biotechnology company’s stock worth $46,669,000 after acquiring an additional 185,929 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Veracyte in the second quarter worth approximately $1,583,000. Congress Asset Management Co. acquired a new position in shares of Veracyte in the third quarter worth approximately $89,971,000. Royal Bank of Canada lifted its stake in shares of Veracyte by 66.4% in the first quarter. Royal Bank of Canada now owns 573,096 shares of the biotechnology company’s stock worth $18,459,000 after acquiring an additional 228,720 shares during the period. Finally, Great Lakes Advisors LLC bought a new stake in Veracyte in the second quarter valued at approximately $3,851,000.

Latest Veracyte News

These are some of the VCYT news items that stood out recently:

• Neutral Sentiment: Veracyte presented at the 2026 UBS Global Healthcare Conference, but the provided transcript listings do not identify new guidance or developments likely to change the outlook. Conference transcript
• Negative Sentiment: A securities-law firm announced an investigation related to Veracyte’s disclosure of Decipher Prostate growth risks. The notice points to below-expectation test volume and narrowed 2026 revenue guidance, which could keep investor attention on execution and legal risk. Investigation notice
• Negative Sentiment: UBS issued a pessimistic forecast for Veracyte, though the supplied report does not provide its specific estimates. Wall Street Zen also cut its rating to “Hold.” UBS forecast report

Veracyte Company Profile

Veracyte, Inc. is a genomic diagnostics company that develops tests to help clinicians diagnose disease and guide treatment decisions, with a focus on cancer and other complex conditions. Its tests analyze biological samples to provide information that can help distinguish between conditions and assess disease risk. The company’s portfolio includes Afirma for thyroid nodule assessment, Decipher for prostate cancer, Prosigna for breast cancer, and Percepta for lung cancer. Veracyte also offers Envisia, a genomic test that supports the diagnosis of idiopathic pulmonary fibrosis and other forms of interstitial lung disease.